Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) have received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $54.00.
RPRX has been the subject of a number of recent analyst reports. UBS Group decreased their target price on Royalty Pharma from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Thursday, February 16th. Morgan Stanley upped their price target on Royalty Pharma from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, April 10th. StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. TheStreet downgraded shares of Royalty Pharma from a “c-” rating to a “d+” rating in a report on Tuesday, February 21st. Finally, Tigress Financial lifted their price objective on shares of Royalty Pharma from $57.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, April 6th.
Royalty Pharma Price Performance
Shares of Royalty Pharma stock opened at $33.63 on Friday. The company’s fifty day simple moving average is $35.29 and its two-hundred day simple moving average is $38.21. The firm has a market cap of $20.42 billion, a PE ratio of 61.15, a price-to-earnings-growth ratio of 0.66 and a beta of 0.42. The company has a quick ratio of 2.36, a current ratio of 2.36 and a debt-to-equity ratio of 0.62. Royalty Pharma has a 12-month low of $32.67 and a 12-month high of $44.66.
Royalty Pharma Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Friday, May 19th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 18th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.38%. Royalty Pharma’s payout ratio is currently 145.45%.
Insider Activity
In related news, CEO Pablo G. Legorreta acquired 160,388 shares of the firm’s stock in a transaction on Tuesday, May 16th. The shares were acquired at an average cost of $33.57 per share, with a total value of $5,384,225.16. Following the completion of the acquisition, the chief executive officer now directly owns 160,388 shares in the company, valued at approximately $5,384,225.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP George W. Lloyd sold 100,000 shares of the stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $37.06, for a total transaction of $3,706,000.00. Following the completion of the transaction, the executive vice president now directly owns 225,000 shares in the company, valued at approximately $8,338,500. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Pablo G. Legorreta bought 160,388 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was purchased at an average cost of $33.57 per share, for a total transaction of $5,384,225.16. Following the transaction, the chief executive officer now owns 160,388 shares of the company’s stock, valued at $5,384,225.16. The disclosure for this purchase can be found here. Insiders sold a total of 133,259 shares of company stock valued at $4,943,087 in the last quarter. 24.86% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Royalty Pharma
Institutional investors have recently modified their holdings of the business. Verition Fund Management LLC grew its position in Royalty Pharma by 282.9% during the 3rd quarter. Verition Fund Management LLC now owns 34,128 shares of the biopharmaceutical company’s stock worth $1,371,000 after purchasing an additional 25,215 shares during the last quarter. Hartford Investment Management Co. raised its holdings in shares of Royalty Pharma by 27.8% in the third quarter. Hartford Investment Management Co. now owns 17,787 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 3,867 shares during the last quarter. Two Sigma Investments LP raised its stake in Royalty Pharma by 68.0% in the 3rd quarter. Two Sigma Investments LP now owns 791,340 shares of the biopharmaceutical company’s stock valued at $31,796,000 after purchasing an additional 320,393 shares during the last quarter. Marshall Wace LLP purchased a new position in Royalty Pharma during the third quarter worth about $17,368,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Royalty Pharma during the 4th quarter worth about $832,000. Institutional investors and hedge funds own 55.36% of the company’s stock.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Read More
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
